Tu Youyou is a Chinese scientist and pharmaceutical chemist whose groundbreaking work in the discovery of artemisinin revolutionized malaria treatment. Her contributions have had a significant impact on global health, saving countless lives. Interestingly, she sought (and found) the award-winning compound in the corpus of Ancient Chinese Medicine.
According to the Nobel Prize website (cited below): “She is the first mainland Chinese scientist to have received a Nobel Prize in a scientific category, and she did so without a doctorate, a medical degree, or training abroad.”
The training of Tu Youyou
Born in Ningbo, Zhejiang, China, Tu’s interest in medicine may have started after she had to miss two years of school after a bout of tuberculosis.
Tu’s interests eventually landed her at Beijing Medical College. There, she studied pharmacology – a modern science – but with a traditional backbone. At college, she learned how to classify medicinal plants and extract their active ingredients in order to learn more about their chemical structure. She would do this with many of the thousands of plants in the ancient Chinese medical handbooks.
Tu Youyou went to work at the Academy of Traditional Chinese Medicine in 1955, after graduation.
She was first asked by the Chinese government to help find a treatment for malaria during the Vietnam War. Vietnamese soldiers were dying in droves because the disease had become resistant to the standard treatment – chloroquine. But this posed a global health threat. She joined the battle against the disease after Chairman Mao Zedong launched a project called Project 523 in 1967.
Discovering a new malaria treatment
In 1969, Tu became the head of Project 523 and traveled to Hainan Island in southern China. She had to leave her two young children behind for three years to study the disease in its deadly habitat.
In Beijing, Tu and her team were facing a difficult situation. Over 240,000 compounds had already been tested for their potential use in anti-malarial drugs, but none worked. That’s when they returned to the ancient Chinese medical text.
A reference to sweet wormwood (known as Artemisia annua) would turn out to be the key. She had identified it for its ability to help with “intermittent fevers” – a key symptom of malaria. It had been used in China around 400 AD.
Through meticulous experimentation, Tu Youyou and her team successfully isolated a compound from Artemisia annua that demonstrated potent anti-malarial properties. She named this compound artemisinin. It was very successful in killing malaria in laboratory tests.
After lab tests came clinical trials, which were also successful. The great thing about artemisinin was that it helped kill malaria while minimizing the development of resistance to the medication. Artemisinin-based combination therapies (ACTs), which combine artemisinin derivatives with other anti-malarial drugs, have since become the gold standard in malaria treatment worldwide.
Tu Youyou’s groundbreaking discoveries earned her numerous accolades and recognition. In 2015, she was awarded the Nobel Prize in Physiology or Medicine, becoming the first Chinese scientist to receive this prestigious honor. Her contributions have had a profound impact on global health, particularly in regions heavily burdened by malaria.
Tu Youyou’s impact on the future
Artemisinin and its derivatives have transformed malaria treatment and played a crucial role in reducing the mortality rate of this deadly disease. Their widespread use has significantly contributed to the decline in malaria-related deaths worldwide. Tu Youyou’s work continues to inspire scientists, researchers, and healthcare professionals in the ongoing fight against malaria.
Despite the remarkable success of artemisinin-based therapies, challenges remain in the battle against malaria. The emergence of drug resistance, particularly in Southeast Asia, underscores the need for ongoing research and innovative approaches to combat this persistent global health issue. Scientists continue to study artemisinin and explore novel drug combinations to stay ahead of the evolving malaria parasite.